Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Use of complementary and alternative medicine (CAM) is common among patients with prostate cancer and has seen an increase among those who are newly diagnosed with the disease, a study has shown. Multivitamins and omega-3 fatty acids are the most commonly used CAMs from 1996 to 2016, while vitamin D use has increased dramatically from 2006 to 2010.
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.
There appears to be an association between low muscle mass and increased risks of recurrence and mortality in patients who undergo radical prostatectomy of prostate cancer regardless of the body mass index (BMI), suggests a recent study.
Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.
Patients with a positive post-treatment biopsy after external beam radiotherapy are at higher risk of distant metastasis and prostate cancer-related death, suggests a recent study. Positive post-treatment biopsies are more frequent in the setting of external beam radiotherapy alone without androgen deprivation therapy or in the presence of high-risk disease.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.
Decision making in men with newly diagnosed favourable-risk prostate cancer is driven by magnetic resonance imaging (MRI) and post-MRI biopsy, according to a study, noting that post-MRI biopsy is a stronger driver of decision making than MRI alone.
Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) more than halved their risk of dying or developing distant metastasis when treated with darolutamide in addition to androgen deprivation therapy (ADT), according to findings of the phase III ARAMIS* trial.
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.